review highlights reproductive options available to patients with each of these chronic viral illnesses and discusses the effectiveness of risk-reducing strategies. The American Society of Reproductive Medicine (ASRM) and the American College of Obstetricians and Gynecologists support the use of risk-reducing strategies in patients with chronic viral illness seeking fertility counseling. These societies encourage ongoing, comprehensive discussion of reproductive options to meet the reproductive goals of patients. [1] [2] [3] Refer to Table 1 for a comparison of reproductive considerations for each of the viruses discussed in this publication.
Laboratory considerations
It should be noted that the use of assisted reproductive technology in patients with chronic viral illness requires special attention in the laboratory setting. ASRM has recommended that samples from viral carriers be processed in a separate laboratory or a designated space within the laboratory to reduce the risk of contamination to other samples. Cross-contamination of samples is possible within liquid nitrogen storage tanks because HIV, hepatitis B, and hepatitis C can survive in liquid nitrogen. 4 Specimens from infected individuals should therefore be stored in separate tanks with containers guaranteed to withstand freezing and thawing, should be stored in liquid nitrogen vapor rather than liquid nitrogen itself, and sperm-washing techniques should be used before freezing to decrease viral load from the samples. [5] [6] [7] Best practice should ensure separate facilities and instruments for processing of infected specimens. If a single laboratory facility is used, careful attention to laboratory protocols is imperative. Batching and staggering the processing of infected samples followed by thorough decontamination can minimize the possibility of viral exposure to uninfected samples. 8 Considerations for HIV An estimated 1.2 million individuals are living with HIV in the United States. 9 Of these individuals, approximately 86% are of reproductive age (15À44 years old), with women comprising 20% of cases. 1 In 2007, heterosexual contact Special considerations must be taken when patients with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C desire to become pregnant. Patients with chronic viral illnesses desire to have children at rates similar to the general population, and options are available to decrease both vertical transmission and viral transmission between partners. Preconception counseling or consultation with fertility specialists is imperative in patients with HIV, hepatitis B, and hepatitis C so that reproductive goals can be addressed and optimized. In couples in which one partner has HIV, the use of highly active antiretroviral therapy or preexposure prophylaxis can significantly reduce the risk of transmission between serodiscordant partners. The use of density gradient sperm-washing techniques and intrauterine insemination or in vitro fertilization results in an apparent lack of transmission of HIV between partners when the male partner is HIV-positive. Vertical transmission of HIV from mother to child can be reduced by use of highly active antiretroviral therapy regimens throughout pregnancy or by cesarean delivery in the setting of high maternal viral load. Transmission of hepatitis B between partners can be eliminated by vaccinating the uninfected partner. Vertical transmission from a hepatitis BÀinfected mother to a child can be reduced by vaccinating neonates with the standard hepatitis B vaccine series as well as hepatitis B immune globulin. Recent data have shown the antiviral medication tenofovir to be an effective way to reduce vertical transmission in the setting of high maternal viral load or the presence of hepatitis B e antigen. There are multiple antiviral medications available to treat chronic hepatitis C, although access to these medications often is limited by cost. Similar to HIV-positive patients, in settings in which the male partner is infected with hepatitis C, density gradient sperm washing can be used before intrauterine insemination or in vitro fertilization to reduce transmission of hepatitis C between partners. No safe and effective method exists to reduce vertical transmission of hepatitis C once a woman becomes pregnant, highlighting the importance of treatment of hepatitis C before pregnancy.
accounted for 32% of new HIV diagnoses in the United States. 10 The percentage of HIV-positive individuals who desire children is between 28% and 45%, which is similar to desired fertility rates seen in the general population.
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Although fertility remains a priority for many individuals living with HIV, this topic often is unaddressed. In a 2011 publication by the San Francisco AIDS Foundation, only 31% of HIV-positive women had discussed fertility plans with a physician. Of those conversations, 64% were initiated by the patient. 12 Providing accurate reproductive counseling to patients with HIV can allow individuals to make informed decisions regarding fertility.
Despite low HIV transmission rates of 0.04% to 0.08% per episode of unprotected intercourse, there are obvious concerns regarding possible viral transmission through attempts to conceive. 13 A study performed before the use of highly active antiretroviral therapy (HAART) showed that in couples with an HIV-positive, untreated male partner, 4.3% of female partners seroconverted to HIV-positive status over the time period necessary h Density-gradient sperm washing unnecessary because male partner is HIV-negative; i After antiviral treatment for hepatitis C, conception should be delayed 6 months due to concerns for possible teratogenicity.
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14 Although a discussion of options such as adoption or the use of donor sperm in the setting of an HIV-positive male partner is appropriate, many couples desire to use their own gametes to conceive. Through the use of HAART or preexposure prophylaxis (PrEP) regimens, transmission rates can be reduced significantly. HAART regimens generally are multidrug treatments given to HIV-positive individuals to decrease viral load. Preliminary results from the European PARTNER study (Partners of People on ART-A New Evaluation of the Risks) show that among 548 serodiscordant heterosexual couples, there were no documented transmissions of HIV when the HIV-positive partner was on HAART and maintained a viral load of less than 200 copies per milliliter. 15 PrEP therapy is prophylactic antiviral medication given to the HIVnegative partner to reduce the risk of acquiring HIV. By taking PrEP therapy consistently, HIV-negative individuals can reduce their risk of becoming infected by 92%. 16 When a couple presents to a physician desiring fertility, the use of HAART and/or PrEP should be recommended because of the highly effective nature of these medications.
In situations in which the male partner is HIV-positive, the use of density gradient sperm washing combined with intrauterine insemination (IUI) or in vitro fertilization (IVF) also has been shown to be an effective way to achieve pregnancy while reducing the risk of HIV transmission to the female partner and neonate. First described in 1998, sperm-washing techniques have been shown repeatedly to result in a lack of apparent viral transmission. 1 A 2011 publication reviewed 17 articles, evaluating a total of 3900 IUI cycles and 738 IVF cycles that were performed with density gradient sperm washing in HIVserodiscordant couples in which the man was HIV-positive. The findings of that review showed no evidence of HIV infection in the female partners or neonates at birth, 3 months postpartum, and 6 months postpartum. 17 Sperm washing is effective because the HIV virus cannot integrate into the spermatozoa and is present only within the seminal fluid. Therefore, even in men with positive serum or semen viral loads, sperm washing removes the seminal fluid and effectively reduces transmission of HIV. 18 When comparing IUI with IVF after appropriate sperm washing, IUI results in predictably lower per cycle pregnancy rates compared with IVF. Pregnancy rates per cycle after IUI are approximately one-fifth to one-half the rates per cycle observed with IVF, although IVF is significantly more costly in most clinical practices. 19 Although there is a theoretically increased risk of viral transmission with IUI due to the increased volume of sample injected compared with IVF, in reality neither IUI nor IVF have resulted in HIV transmission when appropriate washing techniques were used in published studies. 17 As an added layer of assurance, polymerase chain reaction screening can be performed on washed sperm samples before IUI or IVF to ensure that the sample is free of HIV, although detection of HIV occurs in less than 1% of washed samples. 20 In situations in which the female partner is HIV-positive, the most effective way to achieve pregnancy while minimizing risk to the HIV-negative male partner is through IUI or IVF. As discussed previously, HAART and PrEP regimens are extremely effective at reducing the risk of HIV transmission between partners. IUI and IVF, however, eliminate this risk altogether and are therefore the recommended first-line treatment options for partners attempting to conceive. 1 The density gradient sperm washing technique described previously is not necessary when the male partner is HIV-negative.
There has been concern that HIV may negatively impact female fertility, and studies have been conducted to determine whether women with HIV have poorer outcomes when undergoing assisted reproduction. A 2015 publication reviewed 10 studies in which HIV-positive women underwent IVF to achieve pregnancy. In 9 of the 10 studies, HIV-positive women had lower IVF pregnancy rates compared with matched controls. Only one study, however, documented a statistically significant decrease in pregnancy rates. 21 These studies were limited by small sample size and numerous confounders. To date, it remains unclear whether pregnancy rates in HIVpositive women undergoing IVF are truly lower than IVF pregnancy rates for HIV-negative women.
Women with HIV considering pregnancy should be informed of potential risks during pregnancy, including the possibility of opportunistic infections and the potential for transmission of HIV to the fetus during delivery as well as during interventions such as amniocentesis or chorionic villus sampling. Maintaining a low viral load with HAART is crucial. The World Health Organization has published an extensive list of approved HAART regimens during pregnancy.
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Current recommendations support the use of HAART before and throughout pregnancy regardless of maternal CD4 count or viral load.
When low viral loads are maintained, risk of HIV transmission during amniocentesis or chorionic villus sampling appears to be low, although the theoretic risk of transmission cannot be ruled out. 23 Breastfeeding can increase the risk of postnatal transmission, and the Centers for Disease Control and Prevention (CDC) recommends against breastfeeding if replacement feeding is affordable, safe, and feasible. 24 Through the use of HAART during the entire pregnancy and avoidance of breastfeeding, the risk of mother-to-child HIV transmission can be reduced to 1% or less. 25 It should be noted that in 2009 the World Health Organization published recommendations indicating that breastfeeding may be safe and even beneficial in HIV-positive women who adhere to antiretroviral regimens, but the CDC has not adopted these recommendations. 26 The overall reduction in HIV transmission risk using current recommendations is remarkable, considering that without treatment 15%À40% of infants born to Expert Reviews ajog.org HIV-infected mothers ultimately will become infected with HIV. 27 Delivery via scheduled cesarean has been shown to decrease vertical transmission of HIV when maternal viral load is high, specifically greater than 1000 copies per milliliter. 28 Considering the dramatic advancements in HIV management that have been made over the last several years, patients with HIV can be reassured that through the use of risk-reducing strategies, pregnancy can be achieved with relatively low risk of transmission to a partner and fetus. The American Society of Reproductive Medicine published an opinion in 2015 stating there is no ethical reason to withhold fertility services to HIV-infected individuals and couples who are willing to use recommended risk-reducing therapies. 1 The CDC, American College of Obstetricians and Gynecologists, ASRM, and the United States Preventive Services Task Force recommend universal HIV screening as standard of care for adults of reproductive age. 1 Through increased screening and diagnosis, appropriate interventions can be made available to patients with HIV.
Considerations for hepatitis B
Hepatitis B can be either acute or chronic and is transmitted via blood, sexual contact, or vertical transmission. Timing of infection determines the likelihood of progression to chronic infection. Approximately 90% of infants infected with hepatitis B will develop a chronic infection, whereas only 2%À6% of adults who are infected with hepatitis B go on to develop a chronic infection. 2, 29 In 2014, an estimated 850,000 to 2 million individuals were living with chronic hepatitis B in the United States. The United States has a relatively low prevalence of chronic hepatitis B, with less than 2% of the population living with this disease. The global burden of hepatitis B is much greater, with an estimated 240 million infections worldwide. In many countries, particularly in Asia and Africa, greater than 8% of the general population is infected with hepatitis B. 29, 30 In the United States, the rate of new hepatitis B infections has declined by 82% since 1991, largely due to recommendations for universal childhood hepatitis B vaccination. According to the CDC, current childhood vaccination rates in the United States are approximately 92%. 29 Guidelines recommend administering the hepatitis B vaccine to neonates within 24 hours of birth, with 2À3 subsequent doses administered during a 6-month period. The hepatitis B vaccine became commercially available in 1982 and is greater than 95% effective. 31 Prevention of hepatitis B is important, because death from cirrhosis or liver cancer occurs in 25% of chronic infections obtained during childhood and in 15% of infections acquired during adulthood. 29 There is no treatment for acute hepatitis B. There is ongoing research regarding possible treatment for chronic hepatitis B. Treatment options that have been studied include antivirals such as lamivudine, adefovir, telbivudine, entecavir, and interferon alpha 2b. Although these options may slow liver damage, the majority of patients with chronic hepatitis B do not receive treatment for their disease. 32 In late-stage disease, liver transplant may be indicated.
When couples present with one partner who is infected with hepatitis B, it is necessary to ascertain the vaccination status of the uninfected partner. In heterosexual couples in which one partner is infected with hepatitis B, approximately 25% of uninfected partners will become infected with hepatitis B through regular sexual contact if they are unvaccinated or nonimmune. 2 In serodiscordant couples considering pregnancy, viral titers should be drawn on the uninfected partner to determine immune status. If the uninfected partner is nonimmune, the standard hepatitis B vaccination series should be administered as well as hepatitis B immune globulin. 32 Avoidance of sexual contact and possible viral exposure should be observed during the vaccination period, and serum titers should be drawn after completion of the hepatitis B vaccination series to ensure appropriate immunity. Once vaccination is complete, a couple can proceed with attempts to spontaneously conceive because the risk of transmission to the partner has been eliminated through documented immunity. 2 In situations in which a male partner is infected with chronic hepatitis B, vaccination of the female partner has been shown to eliminate the risk of transmission to the mother as well as to the fetus. A study from China published in 2013 evaluated 164 couples in whom male partners were infected with hepatitis B and female partners had been vaccinated against hepatitis B. In testing of amniocentesis and cordocentesis samples from these 164 pregnancies, no fetuses were positive for hepatitis B in utero, implying passive immunity. Furthermore, there were no documented cases of hepatitis B in children at 1 year of life. 33 Infants included in the study received standard neonatal and infant vaccinations.
In male patients who are HIVpositive, sperm-washing techniques have been shown to reduce the risk of viral transmission. In hepatitis B, however, sperm washing is not an effective risk-reducing strategy because hepatitis B DNA can integrate into the spermatozoa itself. 34 Simply removing the seminal plasma does not eliminate the virus, so the use of sperm washing combined with IUI or IVF cannot effectively reduce viral transmission. Once the female partner has been vaccinated against hepatitis B, there is no indication for assisted reproductive technology solely to reduce the risk of viral transmission. 4 In pregnancy, the hepatitis B surface antigen is used to screen women for hepatitis B infection. In situations in which a pregnant woman is seropositive for hepatitis B surface antigen, 10%À 20% of infants will become infected with hepatitis B in the absence of neonatal and infant immunoprophylaxis. If a pregnant woman is also positive for hepatitis B e antigen, a marker of high hepatitis B infectivity, the frequency of vertical transmission approaches 90% in the absence of standard vaccination. 3 
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Vaccination with the hepatitis B vaccine within 12 hours of birth as well as administration of hepatitis B immune globulin reduces risk of mother-to-child transmission, although even with vaccination, infant hepatitis B infection rates range from 8% to 12%. 35 To decrease rates of vertical transmission, recent studies have evaluated maternal treatment of hepatitis B during pregnancy with promising results. A 2016 study conducted by New York University and multiple institutions in China showed that in hepatitis B e antigenÀpositive pregnant women with high viral loads (greater than 200,000 IU per mL), the antiviral tenofovir led to significant decreases in infant hepatitis B infections. In women at high risk for vertical transmission of hepatitis B, the use of tenofovir from 30 weeks' gestation until 4 weeks postpartum in addition to standard vaccination resulted in 5% of infants developing hepatitis B infection, compared with an infant infection rate of 18% when standard vaccination was used alone. 36 During pregnancy, women with hepatitis B should have liver function testing every trimester. 29 Breastfeeding is not contraindicated and does not increase the risk of vertical transmission. Overall, hepatitis B can be prevented through vaccination, so efforts should be made to ensure adequate vaccination before conception; however, in situations in which a pregnant woman is infected with hepatitis B, options exist to decrease rates of transmission to the infant.
Considerations for hepatitis C Approximately 2.7 to 3.9 million individuals are living with hepatitis C in the United States. Hepatitis C can be either acute or chronic, although 75%À80% of patients with hepatitis C develop the chronic form of the disease. In the United States, transmission is primarily blood-borne. Approximately 84% of cases are related to intravenous drug use, with 75%À90% of all intravenous drug users testing positive for hepatitis C. 37 Within 2 years of initiating intravenous drug use, 20%À30% of individuals will become positive for hepatitis C. 37 Although it is possible to contract hepatitis C via sexual contact, this route of transmission is much less common, accounting for only 10% of all infections. In the United States, the number of new cases of hepatitis C has dropped off significantly since the early 1990s, primarily as a result of screening initiatives for blood products and organ donations. Before the implementation of blood and organ donor screening protocols in 1992, 50% of all hepatitis C infections were related to blood transfusions or organ donations. 37 Although there is no vaccine for prevention of hepatitis C, significant advances have been made within the last 5 years to develop antivirals for chronic hepatitis C. Highly effective hepatitis C virus protease inhibitor therapies were first introduced in 2011, and numerous Food and Drug AdministrationÀapproved regimens exist with cure rates of greater than 95% after a 12-to 24-week treatment course. 38 Unfortunately, high cost remains a barrier to access in many cases. In 2016, the mean drug cost per patient was 130,391 US dollars for a 12-week hepatitis C treatment course. 39 If antiviral treatment is pursued, the specific treatment used depends on the viral genotype. There are 6 different genotypes and 50 subtypes of hepatitis C, with genotype 1 being the most common in the United States. 37 In couples who desire pregnancy in which one or both partners are infected with hepatitis C, a frank discussion regarding medical treatment should be held prior to conception. There are no treatment regimens approved for use during pregnancy or breastfeeding. Because of the known teratogenic nature of specific medications such as ribavirin, pregnancy should be delayed for 6 months after treatment, regardless of which partner was treated. During the period of treatment and the 6 months that follow, 2 forms of effective contraception should be used. 4 In situations in which the male partner is infected with hepatitis C, density gradient sperm washing techniques also can be used to minimize risk of transmission to the female partner and the neonate. Similar to what is seen in the setting of HIV, hepatitis C is present only in the seminal plasma, so sperm washing eliminates the virus from the sample that ultimately is used for IUI or IVF. Testing the washed samples for hepatitis C with polymerase chain reaction before IUI or IVF can ensure that the sample is free of virus. 4, 40 Although certain studies have demonstrated lower total sperm count, lower motility, and greater rates of abnormal morphology in semen samples from men with hepatitis C, overall success rates with assisted reproductive technology do not appear to be significantly different than control groups. 41, 42 When female partners with hepatitis C present for preconception counseling, they should be advised that the most effective way to prevent vertical transmission of the virus is through antiviral treatment before pregnancy. 2 Unfortunately, once a woman with hepatitis C becomes pregnant, prevention of transmission to the neonate is lacking. Approximately 6% of infants born to mothers with hepatitis C go on to develop chronic hepatitis C infection, and the risk of hepatitis C transmission to the neonate is increased 2À3 times if the mother is coinfected with HIV. 37 Although hepatitis C has been isolated from breast milk, breastfeeding does not appear to increase the risk of hepatitis C transmission in asymptomatic mothers and is supported by The American College of Obstetricians and Gynecologists and the American Academy of Pediatrics. 43 Regarding testing of infants for infection, it is important to note that hepatitis C antibodies from the mother may be present in the infant's blood until 18 months of age, so testing should be delayed until that time. If there is a need for earlier infant diagnosis, HCV RNA testing can be performed at 1À2 months of age. 37 During pregnancy, as with hepatitis B, Expert Reviews ajog.org liver function tests should be performed every trimester. In addition, with chronic hepatitis B or hepatitis C infections, women should be vaccinated against hepatitis A virus if they are negative for the hepatitis A Immunoglobulin G. Data are lacking regarding the safety of the hepatitis A vaccine series during pregnancy. 28 
Conclusion
Although cost remains one of the most significant barriers to care in this patient population, it is important to recognize that options exist to reduce the risk of transmission of HIV, hepatitis B, and hepatitis C to an uninfected sexual partner and a fetus. Treatment plans are often complex and require a great deal of counseling and ongoing dialogue with patients. It is the responsibility of physicians to open the lines of communication regarding a patient's fertility goals. When these goals are established, an appropriate course of action can then be taken that can maximize the health of patients and children. The reproductive options available to patients with chronic viral illness have undergone dramatic change in the last several years. Health care providers have the unique and important opportunity to support reproductive goals for these patients while minimizing risks of transmission to partners and future offspring. 
